Benign Prostate Hyperplasia Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4166004
- 91 Pages
- January 2021
- Diagnostic and Biotech
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Benign Prostate Hyperplasia Drugs market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Benign Prostate Hyperplasia Drugs market segmented into
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Based on the end-use, the global Benign Prostate Hyperplasia Drugs market classified into
Hospital
Clinic
Others
Competitive Landscape:
Based on geography, the global Benign Prostate Hyperplasia Drugs market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL BENIGN PROSTATE HYPERPLASIA DRUGS INDUSTRY
2.1 Summary about Benign Prostate Hyperplasia Drugs Industry
2.2 Benign Prostate Hyperplasia Drugs Market Trends
2.2.1 Benign Prostate Hyperplasia Drugs Production & Consumption Trends
2.2.2 Benign Prostate Hyperplasia Drugs Demand Structure Trends
2.3 Benign Prostate Hyperplasia Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Alpha Blocker
4.2.2 5-Alpha Reductase Inhibitor
4.2.3 Phosphodiesterase-5 Inhibitor
4.2.4 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
4.3.4 Competitive Landscape:
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Alpha Blocker
5.2.2 5-Alpha Reductase Inhibitor
5.2.3 Phosphodiesterase-5 Inhibitor
5.2.4 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.3.4 Competitive Landscape:
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Alpha Blocker
6.2.2 5-Alpha Reductase Inhibitor
6.2.3 Phosphodiesterase-5 Inhibitor
6.2.4 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.3.4 Competitive Landscape:
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Alpha Blocker
7.2.2 5-Alpha Reductase Inhibitor
7.2.3 Phosphodiesterase-5 Inhibitor
7.2.4 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.3.4 Competitive Landscape:
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Alpha Blocker
8.2.2 5-Alpha Reductase Inhibitor
8.2.3 Phosphodiesterase-5 Inhibitor
8.2.4 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.3.4 Competitive Landscape:
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Alpha Blocker
9.2.2 5-Alpha Reductase Inhibitor
9.2.3 Phosphodiesterase-5 Inhibitor
9.2.4 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.3.4 Competitive Landscape:
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sanofi
10.1.2 Coloplast
10.1.3 Pfizer
10.1.4 Merck
10.1.5 GlaxoSmithKline
10.1.6 Eli Lilly and Company
10.1.7 Abbott Laboratories
10.1.8 Teva Pharmaceuticals
10.1.9 Allergan
10.1.10 Boehringer Ingelheim
10.2 Benign Prostate Hyperplasia Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Sanofi
10.2.2 Coloplast
10.2.3 Pfizer
10.2.4 Merck
10.2.5 GlaxoSmithKline
10.2.6 Eli Lilly and Company
10.2.7 Abbott Laboratories
10.2.8 Teva Pharmaceuticals
10.2.9 Allergan
10.2.10 Boehringer Ingelheim
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1.Table Benign Prostate Hyperplasia Drugs Product Type Overview
2.Table Benign Prostate Hyperplasia Drugs Product Type Market Share List
3.Table Benign Prostate Hyperplasia Drugs Product Type of Major Players
4.Table Brief Introduction of Sanofi
5.Table Brief Introduction of Coloplast
6.Table Brief Introduction of Pfizer
7.Table Brief Introduction of Merck
8.Table Brief Introduction of GlaxoSmithKline
9.Table Brief Introduction of Eli Lilly and Company
10.Table Brief Introduction of Abbott Laboratories
11.Table Brief Introduction of Teva Pharmaceuticals
12.Table Brief Introduction of Allergan
13.Table Brief Introduction of Boehringer Ingelheim
14.Table Products & Services of Sanofi
15.Table Products & Services of Coloplast
16.Table Products & Services of Pfizer
17.Table Products & Services of Merck
18.Table Products & Services of GlaxoSmithKline
19.Table Products & Services of Eli Lilly and Company
20.Table Products & Services of Abbott Laboratories
21.Table Products & Services of Teva Pharmaceuticals
22.Table Products & Services of Allergan
23.Table Products & Services of Boehringer Ingelheim
24.Table Market Distribution of Major Players
25.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
26.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
27.Table Global Benign Prostate Hyperplasia Drugs Market Forecast (Million USD) by Region 2021f-2026f
28.Table Global Benign Prostate Hyperplasia Drugs Market Forecast (Million USD) Share by Region 2021f-2026f
29.Table Global Benign Prostate Hyperplasia Drugs Market Forecast (Million USD) by Demand 2021f-2026f
30.Table Global Benign Prostate Hyperplasia Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
Biomaterials are materials of either synthetic or natural origin that are used for interaction with biological systems for medical purposes such as treating or repairing damage tissues. They are used in joint replacements, plastic surgeries, drug delivery devi...
- Publish Date: September 1, 2016
- $5370
The global DNA sequencing market was estimated to be $6,243 million in 2017 and is projected to reach $25,470 million in 2025 growing with a CAGR of 19% from 2018 to 2025. DNA sequencing is a type of technology in which several DNA strands can be sequenced through massive parallelization. The DNA sequencing contains both Sanger’s method of sequencing and non-Sanger’s methods of sequencing. ...
- Publish Date: May 24, 2017
- $5370
Patients with serious nervous system injuries or strokes often require lifelong assistance, which burdens patients, their families, and society. Innovative, paradigm shifting strategies are required to develop treatments for neurological injury. Early dia...
- Publish Date: May 24, 2017
- $5370
